TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy ...

Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...

PMN310 is a humanized monoclonal antibody (mAb) designed and developed to selectively target only soluble amyloid-beta ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the ...

Kangpu Biopharmaceuticals, Ltd. ('Kangpu') today announced that the Company has received IND approval from the CDE (Center ...

The US Food and Drug Administration (FDA) has approved label changes for Sublocade (buprenorphine extended-release), ...

Health care providers can now administer Sublocade subcutaneously into the thigh, buttock, or the back of the upper arm, in addition to the abdomen.

The main growth driver for Alkermes going forward will be ALKS 2680. Read why I maintain my buy rating on ALKS stock.

The FDA has lifted its hold and has given Entrada Therapeutics permission to launch a Phase 1b clinical trial to test ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...